EP1135361A1 - Therapeutic product and its use - Google Patents

Therapeutic product and its use

Info

Publication number
EP1135361A1
EP1135361A1 EP99973016A EP99973016A EP1135361A1 EP 1135361 A1 EP1135361 A1 EP 1135361A1 EP 99973016 A EP99973016 A EP 99973016A EP 99973016 A EP99973016 A EP 99973016A EP 1135361 A1 EP1135361 A1 EP 1135361A1
Authority
EP
European Patent Office
Prior art keywords
tramadol
enantiomer
product according
treatment
racemic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP99973016A
Other languages
German (de)
French (fr)
Inventor
Hazel Darwin Discovery Ltd. Bardsley
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Darwin Discovery Ltd
Original Assignee
Darwin Discovery Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9826537.4A external-priority patent/GB9826537D0/en
Priority claimed from GBGB9826536.6A external-priority patent/GB9826536D0/en
Priority claimed from GBGB9826535.8A external-priority patent/GB9826535D0/en
Application filed by Darwin Discovery Ltd filed Critical Darwin Discovery Ltd
Publication of EP1135361A1 publication Critical patent/EP1135361A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/133—Amines having hydroxy groups, e.g. sphingosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer

Definitions

  • the present invention relates to a novel, non-racemic, form of tramadol, and its use in analgesia.
  • Tramadol ( ⁇ is-2-dimethylaminomethyl-l- (3-methoxy- phenyl)-l-cyclohexanol) is a chiral drug substance which is used as a high-potency analgesic agent.
  • tramadol is currently marketed as the racemate only, there has been considerable interest in the physiological properties associated with its individual enantiomers, namely 1S, 2S- (-) -tramadol and lR, 2R- ⁇ +) -tramadol, the latter being shown below (1) .
  • the present invention is based on the discovery that, by employing certain, non-racemic, proportions of the respective enantiomers of tramadol, the most beneficial therapeutic index, in terms of analgesic efficacy and reduction of side effects (e.g. nausea, vomiting, dizziness, constipation, sedation and others) associated with administration of the racemate, may be achieved.
  • a product comprises a non-racemic mixture of the single enantiomers of tramadol as a combined preparation (kit) for simultaneous, separate or sequential use in the treatment or prevention of pain.
  • a non-racemic mixture of the single enantiomers of tramadol is used in the manufacture of a medicament for the treatment or prevention of pain, and is particularly useful for the treatment of patients disposed to side effects typically associated with the administration of racemic tramadol.
  • the medicament is, however, useful in treating other patient types, as discussed below.
  • a product comprises a non-racemic mixture of the single enantiomers of tramadol and a pharmaceutically-acceptable carrier.
  • the non-racemic mixture for use in the present invention comprises at least 60 wt.% (-) -tramadol. While enantiomerically-pure (-) -tramadol may be useful in achieving analgesia, it is preferred that (-) -tramadol be formulated with at least some (+) -tramadol, as with both enantiomers present the optimal balance between analgesic efficacy and safety is achieved.
  • weight ratios of the two enantiomers lie in the range 10- 40:90-60 (+) -tramadol: (-) -tramadol (+:-), more preferred ratios lie in the range 20-40:80-60 (+:-), and the most preferred ratios lie in the range 30-40:70-60 (+:-) .
  • racemic tramadol preferred non-racemic mixtures are particularly useful in the treatment of patients who are disposed to side effects typically associated with the administration of racemic tramadol.
  • side effects typically observed in the administration of racemic tramadol include blurred vision, drowsiness, somnolence, hallucinations, respiratory depression, and euphoria.
  • the present invention is particularly useful in treating those patients prone to nausea and vomiting. This is because, as is explained in the Example below, (-) -tramadol is believed to modulate the emetic properties of (+)- tramadol, thereby reducing the overall emetic capability of racemic tramadol. This effect can be exploited for maximum benefit using different release profiles for the different enantiomers, as is discussed below.
  • the present invention is also believed to be particularly suited to the treatment of patients exhibiting abnormal CYP2D6 liver enzyme activity.
  • the CYP2D6 gene encoding sparteine oxygenase is highly polymorphic, and an ever-increasing number of mutations are being identified.
  • the wild-type gene is CYP2D6*1A. Any person not having the wild-type gene can be categorised as exhibiting abnormal enzyme activity. The precise nature of any particular mutation determines the degree to which a patient exhibits abnormal enzyme activity. Thus, by applying simple laboratory genetic analysis techniques it is possible to ascertain the approximate rate at which (+) -tramadol will be metabolised by a particular patient, and therefore how rapid and effective analgesia will be.
  • mixtures comprising a very high proportion of (-) -tramadol may be used, for example weight ratios in the range 0-10:100-90 (+:-), with patients particularly disposed to side effects associated with racemic tramadol.
  • Another option is to employ a more even balance of the two enantiomers, with the more efficacious (+) -enantiomer in excess, for instance weight ratios in the range 60-80:40-20 (+:-), typically 60-70:40- 30 (+:-).
  • Such ratios may be useful in treating patients not particularly disposed to side effects associated with racemic tramadol, or where analgesic efficacy is of primary importance.
  • Administration of (-) -tramadol before or at a faster rate than (+) -tramadol would, however, still be beneficial in reducing side effects.
  • a further aspect of the present invention is the use of a non-racemic mixture of the single enantiomers of tramadol in the manufacture of a medicament for the prevention or treatment of migraine.
  • the amount of non-racemic tramadol administered to any particular patient will depend upon the patient and the conditions for which the non-racemic tramadol is administered, and on whether non-racemic tramadol is to be used in prophylaxis or in therapy.
  • Suitable amounts for administration are readily derivable by the skilled person.
  • the different enantiomers of tramadol may be administered simultaneously, separately or sequentially. They may be formulated for either immediate or controlled release, or a combination of the two, or for release at different rates, or at different times.
  • Preferred modes of administration release (-) -tramadol before or at a faster rate than (+) -tramadol, so as to optimise the effect of (-) -tramadol on the emetic properties of (+) -tramadol.
  • situations may be envisaged, where the reverse may be required, and it is desired to administer (+)- tramadol before or at a faster rate than (-) -tramadol.
  • a particularly preferred mode of administration is with (-) -tramadol in immediate release form and (+)- tramadol in controlled release form, by employing a combination of immediate and controlled release technologies, as described in WO-A-9840053 , the contents of which are incorporated herein by way of reference. It is envisaged that a dosage form of this type may be particularly beneficial in achieving rapid analgesia without the concomitant side effects associated with administration of racemic tramadol.
  • a number of different types of dosage form can be envisaged for the non-racemic mixtures of the present invention, for administration by a variety of routes, e.g. oral, rectal, transdermal, nasal, ophthalmic, pormonary and injectable (subcutaneous or intravenous) .
  • Suitable dosage forms include, for example, tablets, suppositories, capsules, e.g. containing multiparticulates, patches, polymer implants, aerosols, liposomes or microparticulates for injection, and any other conventional dosage form. Particularly preferred dosage forms are described in WO-A-9840053.
  • a bilayered tablet is particularly preferred, including (-) -tramadol for immediate release in one layer and (+) -tramadol for controlled release in another layer.
  • the results upon which the present invention are based are reported in the following Example.
  • the objective was to identify the optimal range of enantiomeric ratios capable of providing the most beneficial therapeutic index, in terms of both analgesic efficacy and reduction of the nausea and vomiting associated with racemic tramadol.
  • test substances Different amounts of each of the test substances were orally administered to rats, using a constant dose volume of 10 ml/kg.
  • 0.1 ml of a 20% w/v suspension of Brewer's yeast in saline was injected subcutaneously into the plantar surface of the right hand paw of each rat to induce hyper-algesia.
  • the left hind paw was similarly injected with 0.1 ml saline, as a control.
  • Measurements of pressure tolerated were taken from the left (non-inflamed) and right (inflamed) paws 30 minutes after administration of the test substance.
  • (+) -tramadol is seen to be non-emetic at doses of up to 200 mg/kg.
  • (+) -tramadol induces nausea in 75% of ferrets at 50 mg/kg, while the racemate causes nausea in 25% of animals at 100 mg/kg.
  • the racemate is a 50:50 mixture of the two enantiomers it is seen to induce less nausea than would be expected based on its content of (+)- enantiomer. This disparity can be explained by the ability of the (-) -enantiomer to modulate emesis associated with the (+) -enantiomer.

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

The present invention is based on the discovery that, by employing certain, non-racemic, proportions of the respective enantiomers of tramadol, the most beneficial therapeutic index, in terms of analgesic efficacy and reduction of side effects (e.g. nausea, vomiting, dizziness, constipation, sedation and others) associated with administration of the racemate, may be achieved.

Description

THERAPEUTIC PRODUCT AND ITS USE
Field of the Invention
The present invention relates to a novel, non-racemic, form of tramadol, and its use in analgesia. Background of the Invention
Tramadol (σis-2-dimethylaminomethyl-l- (3-methoxy- phenyl)-l-cyclohexanol) is a chiral drug substance which is used as a high-potency analgesic agent. Although tramadol is currently marketed as the racemate only, there has been considerable interest in the physiological properties associated with its individual enantiomers, namely 1S, 2S- (-) -tramadol and lR, 2R- {+) -tramadol, the latter being shown below (1) .
In particular, the analgesic efficacy and safety of the racemate and the individual enantiomers have been investigated in a randomised, double-blind study with gynaecological patients using intravenous patient- controlled analgesia; see S. Grond et al. Pain (1995) 62 (3) :313-320. Although (+) -tramadol appeared to be more potent in producing analgesia, it also produced more nausea and vomiting. Since the racemate has more efficacy than (-) -tramadol and no more side effects than (+) -tramadol, the authors concluded that the racemate had more clinical utility.
In another study it was shown that there is complementary and synergistic antinociceptive interaction between the individual enantiomers of tramadol; see R.B. Raffa et al , J Pharmacol. Exp. Ther. (1993) 267m : 331- 340. The enantiomers have different potencies at opioid receptors, and in inhibiting serotonin re-uptake and noradrenaline re-uptake. It therefore appears that both enantiomers of tramadol contribute to the analgesic effect. Summary of the Invention
The present invention is based on the discovery that, by employing certain, non-racemic, proportions of the respective enantiomers of tramadol, the most beneficial therapeutic index, in terms of analgesic efficacy and reduction of side effects (e.g. nausea, vomiting, dizziness, constipation, sedation and others) associated with administration of the racemate, may be achieved.
According to a first aspect of the present invention a product comprises a non-racemic mixture of the single enantiomers of tramadol as a combined preparation (kit) for simultaneous, separate or sequential use in the treatment or prevention of pain.
According to a second aspect of the present invention, a non-racemic mixture of the single enantiomers of tramadol is used in the manufacture of a medicament for the treatment or prevention of pain, and is particularly useful for the treatment of patients disposed to side effects typically associated with the administration of racemic tramadol. The medicament is, however, useful in treating other patient types, as discussed below.
According to a third aspect of the claimed invention, a product comprises a non-racemic mixture of the single enantiomers of tramadol and a pharmaceutically-acceptable carrier. Detailed Description of the Invention
In the context of the present Application, when reference is made to a non-racemic mixture of tramadol this is intended to include enantiomerically-pure (-) -tramadol, or enantiomeric excesses in respect of (-) -tramadol approaching enantiomeric purity.
Typically, the non-racemic mixture for use in the present invention comprises at least 60 wt.% (-) -tramadol. While enantiomerically-pure (-) -tramadol may be useful in achieving analgesia, it is preferred that (-) -tramadol be formulated with at least some (+) -tramadol, as with both enantiomers present the optimal balance between analgesic efficacy and safety is achieved. Particularly preferred weight ratios of the two enantiomers lie in the range 10- 40:90-60 (+) -tramadol: (-) -tramadol (+:-), more preferred ratios lie in the range 20-40:80-60 (+:-), and the most preferred ratios lie in the range 30-40:70-60 (+:-) .
These preferred non-racemic mixtures are particularly useful in the treatment of patients who are disposed to side effects typically associated with the administration of racemic tramadol. A couple of examples of such side effects are given above. Other side effects typically observed in the administration of racemic tramadol include blurred vision, drowsiness, somnolence, hallucinations, respiratory depression, and euphoria. The present invention, however, is particularly useful in treating those patients prone to nausea and vomiting. This is because, as is explained in the Example below, (-) -tramadol is believed to modulate the emetic properties of (+)- tramadol, thereby reducing the overall emetic capability of racemic tramadol. This effect can be exploited for maximum benefit using different release profiles for the different enantiomers, as is discussed below.
The present invention is also believed to be particularly suited to the treatment of patients exhibiting abnormal CYP2D6 liver enzyme activity. The CYP2D6 gene encoding sparteine oxygenase is highly polymorphic, and an ever-increasing number of mutations are being identified. The wild-type gene is CYP2D6*1A. Any person not having the wild-type gene can be categorised as exhibiting abnormal enzyme activity. The precise nature of any particular mutation determines the degree to which a patient exhibits abnormal enzyme activity. Thus, by applying simple laboratory genetic analysis techniques it is possible to ascertain the approximate rate at which (+) -tramadol will be metabolised by a particular patient, and therefore how rapid and effective analgesia will be. In accordance with the present invention it is envisaged that patients phenotypically or genotypically diagnosed as extensive metabolizers of racemic tramadol will particularly benefit from administration of non- racemic tramadol, since they are especially prone to side- effects such as nausea and vomiting. Furthermore, the administration regime may be tailored to suit any individual patient once his or her CYP2D6 genotype is known. Other non-racemic ratios of the two tramadol enantiomers are also useful in the treatment or prevention of pain, depending upon the cause of the pain and/or the patient to be treated. For instance, mixtures comprising a very high proportion of (-) -tramadol may be used, for example weight ratios in the range 0-10:100-90 (+:-), with patients particularly disposed to side effects associated with racemic tramadol. Another option is to employ a more even balance of the two enantiomers, with the more efficacious (+) -enantiomer in excess, for instance weight ratios in the range 60-80:40-20 (+:-), typically 60-70:40- 30 (+:-). Such ratios may be useful in treating patients not particularly disposed to side effects associated with racemic tramadol, or where analgesic efficacy is of primary importance. Administration of (-) -tramadol before or at a faster rate than (+) -tramadol would, however, still be beneficial in reducing side effects.
In the context of the present Application, all quoted weight ratios should be interpreted as including a tolerance of, say, ± 5 wt.%. The present invention is also believed to be particularly useful in the treatment of the pain and/or other effects associated with migraine. To this end, a further aspect of the present invention is the use of a non-racemic mixture of the single enantiomers of tramadol in the manufacture of a medicament for the prevention or treatment of migraine. The amount of non-racemic tramadol administered to any particular patient will depend upon the patient and the conditions for which the non-racemic tramadol is administered, and on whether non-racemic tramadol is to be used in prophylaxis or in therapy. Suitable amounts for administration are readily derivable by the skilled person. The different enantiomers of tramadol may be administered simultaneously, separately or sequentially. They may be formulated for either immediate or controlled release, or a combination of the two, or for release at different rates, or at different times. Preferred modes of administration release (-) -tramadol before or at a faster rate than (+) -tramadol, so as to optimise the effect of (-) -tramadol on the emetic properties of (+) -tramadol. Although, situations may be envisaged, where the reverse may be required, and it is desired to administer (+)- tramadol before or at a faster rate than (-) -tramadol.
A particularly preferred mode of administration is with (-) -tramadol in immediate release form and (+)- tramadol in controlled release form, by employing a combination of immediate and controlled release technologies, as described in WO-A-9840053 , the contents of which are incorporated herein by way of reference. It is envisaged that a dosage form of this type may be particularly beneficial in achieving rapid analgesia without the concomitant side effects associated with administration of racemic tramadol.
A number of different types of dosage form can be envisaged for the non-racemic mixtures of the present invention, for administration by a variety of routes, e.g. oral, rectal, transdermal, nasal, ophthalmic, pormonary and injectable (subcutaneous or intravenous) . Suitable dosage forms include, for example, tablets, suppositories, capsules, e.g. containing multiparticulates, patches, polymer implants, aerosols, liposomes or microparticulates for injection, and any other conventional dosage form. Particularly preferred dosage forms are described in WO-A-9840053. Of the dosage forms described in that document, a bilayered tablet is particularly preferred, including (-) -tramadol for immediate release in one layer and (+) -tramadol for controlled release in another layer. The results upon which the present invention are based are reported in the following Example. Example
The objective was to identify the optimal range of enantiomeric ratios capable of providing the most beneficial therapeutic index, in terms of both analgesic efficacy and reduction of the nausea and vomiting associated with racemic tramadol.
Two studies were carried out to determine analgesic efficacy and emesis of tramadol and its enantiomers in the rat and the ferret, respectively. Comparison of the data obtained in these studies enabled determination of a range of optimal enantiomeric ratios for these species. Pharmacokinetic/ pharmacodynamic modelling allowed this data to be extrapolated to humans. Assessment of Analgesic Efficacy
Tramadol and its pure enantiomers were examined for their analgesic efficacy in the rat using the Randall- Selitto test (Arch. Int. Pharmacodyn. (1957) 111:409-419) in the rat. This test was designed to measure the effect of tramadol and its enantiomers on yeast-induced analgesia, with pain perception being assessed by an increased by increase in pressure to the paw using an analgesy meter. For comparative purposes the effects of the active metabolites of the tramadol enantiomers, 0- desmethyltramadol, were also tested.
Different amounts of each of the test substances were orally administered to rats, using a constant dose volume of 10 ml/kg. Immediately following administration, 0.1 ml of a 20% w/v suspension of Brewer's yeast in saline was injected subcutaneously into the plantar surface of the right hand paw of each rat to induce hyper-algesia. The left hind paw was similarly injected with 0.1 ml saline, as a control.
Measurements of pressure tolerated were taken from the left (non-inflamed) and right (inflamed) paws 30 minutes after administration of the test substance.
The results observed are illustrated in Figure 1, for the inflamed paw, and Figure 2, for the non-inflamed paw, as a percentage increase in pain tolerance with varying doses of test substance. In both Figures, T = tramadol and Ml = O-desmethyltramadol. Assessment of Nausea
Tramadol and its pure enantiomers were examined for their nauseous effects in the ferret. For comparative purposes the effects of the active metabolite of (+)- tramadol, (+) -O-desmethyltramadol ((+)-Ml), were also tested. Orally-dosed ferrets were observed over a period of 4 hours for signs of retching and vomiting. Any ferret that retched or vomited over the 4-hour period was regarded as a responder, i.e. as exhibiting nausea. The results are illustrated in Figure 3; T and Ml represent tramadol and O-desmethyltramadol, as in Figures 1 and 2. As expected, (+)-Ml is highly emetic. (-) -tramadol is seen to be non-emetic at doses of up to 200 mg/kg. In comparison, (+) -tramadol induces nausea in 75% of ferrets at 50 mg/kg, while the racemate causes nausea in 25% of animals at 100 mg/kg. Although the racemate is a 50:50 mixture of the two enantiomers it is seen to induce less nausea than would be expected based on its content of (+)- enantiomer. This disparity can be explained by the ability of the (-) -enantiomer to modulate emesis associated with the (+) -enantiomer.
Bioanalysis of plasma samples and liver microsome analysis have shown that tramadol is metabolised similarly in the rat, the ferret and the human. It is therefore possible to compare the data obtained in each of these studies, to arrive at the optimal range of enantiomeric ratios for these species. Furthermore, by pharmacokinetic/ pharmacodynamic modelling techniques, it is possible to extrapolate the data obtained to humans, to arrive at the optimal range of enantiomeric ratios for use in the present invention.

Claims

Claims
1. A product comprising a non-racemic mixture of the single enantiomers of tramadol as a combined preparation (kit) for simultaneous, separate or sequential use in the treatment or prevention of pain, the mixture comprising at least some (-) -tramadol.
2. A product according to claim 1, which comprises at least 60% by weight (-) -tramadol.
3. A product according to claim 2 in which the single enantiomers are in a weight ratio of 10-40:90-60 (+:-).
4. A product according to claim 2 in which the single enantiomers are in a weight ratio of 20-40:80-60 (+:-).
5. A product according to claim 2 in which the single enantiomers are in a weight ratio of 0-20:100-80 (+:-).
6. A product according to any preceding claim, which releases the (-) -enantiomer before the (+) -enantiomer.
7. A product according to any of claims 1 to 5, which releases the (-) -enantiomer faster than the (+) -enantiomer.
8. A product according to any of claims 1 to 5, wherein the (-) -enantiomer is in immediate release form and the (+) -enantiomer is in controlled release form.
9. Use of a non-racemic mixture as defined in any of claims 1 to 5 in the manufacture of a medicament for the treatment or prevention of pain.
10. Use according to claim 9, wherein the pain is pain associated with migraine.
11. Use according to claim 9, which is for the treatment of a patient disposed to side effects associated with administration of racemic tramadol.
12. Use according to claim 11, wherein the side effects are selected from nausea, vomiting, dizziness, constipation, sedation, blurred vision, drowsiness, somnolence, hallucinations, respiratory depression, and emporia, especially nausea and vomiting.
13. Use according to claim 9 , which is for the treatment of a exhibiting abnormal CYP2D6 liver enzyme activity.
14. Use of a non-racemic mixture as defined in any of claims 1 to 5 in the manufacture of a medicament for the for the treatment or prevention of migraine.
15. A product comprising a non-racemic mixture as defined in any of claims 1 to 5, and a pharmaceutically-acceptable carrier.
16. A product according to claim 15 , which releases the (-) -enantiomer before the (+) -enantiomer.
17. A product according to claim 15, which releases the (-) -enantiomer faster than the (+) -enantiomer.
18. A product according to claim 15, wherein the (-)- enantiomer is in immediate release form and the (+)- enantiomer is in controlled release form.
19. A product according to any of claims 15 to 18 , which comprises the two enantiomers in separate portions thereof.
20. A product according to claim 19, which is a bilayered tablet comprising (-) -tramadol in one portion thereof, and (+) -tramadol in another, separate, portion thereof.
EP99973016A 1998-12-02 1999-12-02 Therapeutic product and its use Withdrawn EP1135361A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GB9826536 1998-12-02
GBGB9826537.4A GB9826537D0 (en) 1998-12-02 1998-12-02 Therapeutic product and its use
GB9826537 1998-12-02
GBGB9826536.6A GB9826536D0 (en) 1998-12-02 1998-12-02 Therapeutic product and its use
GBGB9826535.8A GB9826535D0 (en) 1998-12-02 1998-12-02 Therapeutic product and its use
GB9826535 1998-12-02
PCT/GB1999/004021 WO2000032558A1 (en) 1998-12-02 1999-12-02 Therapeutic product and its use

Publications (1)

Publication Number Publication Date
EP1135361A1 true EP1135361A1 (en) 2001-09-26

Family

ID=27269570

Family Applications (1)

Application Number Title Priority Date Filing Date
EP99973016A Withdrawn EP1135361A1 (en) 1998-12-02 1999-12-02 Therapeutic product and its use

Country Status (12)

Country Link
EP (1) EP1135361A1 (en)
JP (1) JP2002531431A (en)
KR (1) KR20010080364A (en)
CN (1) CN1329590A (en)
AU (1) AU1400100A (en)
BR (1) BR9915873A (en)
CA (1) CA2350635A1 (en)
HU (1) HUP0104420A2 (en)
IL (1) IL142778A0 (en)
NO (1) NO20012738L (en)
PL (1) PL347542A1 (en)
WO (1) WO2000032558A1 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1164601A (en) 1999-11-09 2001-06-06 Darwin Discovery Limited Therapeutic use and formulation
BR0114395A (en) * 2000-10-03 2005-08-16 Penwest Pharmaceuticals Compan Pharmaceutical composition for oral supply administration
DE10108122A1 (en) 2001-02-21 2002-10-02 Gruenenthal Gmbh Medicines based on tramadol
WO2003048113A1 (en) 2001-11-30 2003-06-12 Sepracor Inc. Tramadol analogs and uses thereof
RU2008113439A (en) 2005-09-09 2009-10-20 Лабофарм Инк. (CA) COMPOSITIONS WITH SLOW DELIVERY OF A MEDICINAL PRODUCT
NZ579170A (en) 2007-02-12 2012-05-25 Dmi Biosciences Inc Reducing side effects of tramadol
BRPI0811639A2 (en) * 2007-05-31 2014-09-30 Sepracor Inc FENY CYCLOAKILAMINES REPLACED AS MONOAMINE RECAPTATION INHIBITORS
JOP20190251A1 (en) * 2017-05-31 2019-10-21 Metys Pharmaceuticals AG Synergistic compositions comprising (r)-dimiracetam (1) and (s)-dimiracetam (2) in a non-racemic ratio
WO2019113079A1 (en) 2017-12-05 2019-06-13 Sunovion Pharmaceuticals Inc. Nonracemic mixtures and uses thereof
WO2019113084A1 (en) 2017-12-05 2019-06-13 Sunovion Pharmaceuticals Inc. Crystal forms and production methods thereof
BR112021024380A2 (en) 2019-06-04 2022-04-19 Sunovion Pharmaceuticals Inc Modified release formulations and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5204116A (en) * 1991-05-01 1993-04-20 Alza Corporation Dosage form providing immediate therapy followed by prolonged therapy
BR9808325A (en) * 1997-03-11 2000-05-16 Darwin Discovery Ltd Dosage forms comprising separate portions of r- and senanciÈmeros
DE19807535A1 (en) * 1998-02-21 1999-08-26 Asta Medica Ag Drug combination for treating migraine, migraine-type headaches or pain accompanied by nausea, vomiting or delayed gastric emptying

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO0032558A1 *

Also Published As

Publication number Publication date
NO20012738D0 (en) 2001-06-01
WO2000032558A1 (en) 2000-06-08
AU1400100A (en) 2000-06-19
CA2350635A1 (en) 2000-06-08
JP2002531431A (en) 2002-09-24
CN1329590A (en) 2002-01-02
KR20010080364A (en) 2001-08-22
NO20012738L (en) 2001-06-01
PL347542A1 (en) 2002-04-08
BR9915873A (en) 2001-08-21
HUP0104420A2 (en) 2002-08-28
IL142778A0 (en) 2002-03-10

Similar Documents

Publication Publication Date Title
Teoh et al. Oral manifestations of illicit drug use
O’Brien Drug addiction and drug abuse
Grond et al. Clinical pharmacology of tramadol
Bem et al. Dextromethorphan: an overview of safety issues
US5502080A (en) Combined use of dopamine and serotonin agonists in the treatment of allergic disorders
NO302736B1 (en) Pharmaceutical preparation comprising tramadol and ibuprofen
KR19990028983A (en) Composition consisting of di-threo-methylphenidate and other agents
CN114712356A (en) Combination of dextromethorphan and bupropion for the treatment of depression
WO2000032558A1 (en) Therapeutic product and its use
US6297286B1 (en) Therapeutic use and formulation
EP2002828B1 (en) Solid pharmaceutical preparation
Mystakidou et al. Oral transmucosal fentanyl citrate for the treatment of breakthrough pain in cancer patients: an overview of its pharmacological and clinical characteristics
EP0759299A1 (en) Potentiation of serotonin response
DE69918322T2 (en) USE OF OPTICALLY PURE (R) -TOFIZOPAM FOR THE TREATMENT AND PREVENTION OF APPEARANCE
EP1181015A2 (en) Methods for treating apnea and apnea disorders using optically pure r(+)ondansetron
EP1795207A1 (en) Solid pharmaceutical preparation
CA2423558A1 (en) Delivery system for multi-pharmaceutical active materials at various release rates
Likar et al. Challenging the equipotency calculation for transdermal buprenorphine: four case studies
WO2003070155A2 (en) Orally administrable pharmaceutical formulation
GB2249724A (en) Use of lithium salts to increase life-expectancy
MXPA01005242A (en) Therapeutic product and its use
RU2506947C2 (en) Prolonged release tablet containing theobromin
CA2338326A1 (en) Use of moclobemide and metabolites for treating and preventing substance abuse
US20160317662A1 (en) Stable oral pharmaceutical composition
WO2000006138A2 (en) Use of moclobemide for treating pain and other diseases

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20010625

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

17Q First examination report despatched

Effective date: 20021230

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20030510

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1038003

Country of ref document: HK